The trademark application REYVOWE was filed by Eli Lilly and Company, a U.S. corporation (the "Applicant"). The application was published for oppositions on November 20, 2017, and it was registered by office on February 26, 2018 without any oppositions.
The application was filed in English (Italian was selected as the second language).
Change of name and professional address of the trademark registration was recorded on December 19, 2018. Appointment and Replacement of representative of the trademark registration was recorded on April 4, 2019.
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, prevention and/ or diagnosis of Alzheimer's disease, anxiety disorders, atopic dermatitis, autoimmune diseases and disorders, axial spondyloarthritis, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders
Pharmaceutical preparations for the treatment, prevention and/ or diagnosis of gastrointestinal diseases and disorders, hypoglycemia, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, and liver diseases and disorders
Pharmaceutical preparations for the treatment, prevention and/ or diagnosis of mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, Parkinson's disease, Psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, sleep disorders, spondyloarthropathy, systemic lupus erythematosus, ulcerative colitis
Diagnostic agents and substances for medical purposes
Radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases.